SRPT

Business Context and Reporting Period

Company: AVI BioPharma, Inc. (Note: Input metadata referenced Sarepta Therapeutics, but the filing text is for AVI BioPharma).

Reporting Period: Fiscal year ended December 31, 2009.

Business Overview: AVI BioPharma is a biopharmaceutical company specializing in the discovery and development of RNA-based drugs using proprietary phosphordiamidate morpholino oligomer (PMO) chemistry. The company focuses on genetic diseases (specifically Duchenne Muscular Dystrophy) and infectious diseases (Ebola, Marburg, H1N1). It has no commercial products for sale and relies on government contracts, grants, and strategic alliances for revenue.

Key Financial Metrics

Debt and Liquidity: The company holds minimal long-term debt ($2.0 million total, secured by real estate). Liquidity improved significantly in 2009 due to two equity financing rounds raising net proceeds of $47.8 million. Management believes cash is sufficient to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 17% to $17.6 million, primarily due to lower activity levels in government research contracts (DTRA Ebola, Marburg, and Junin programs).
• Operating Loss Improvement: Operating loss narrowed significantly to $15.5 million from $27.5 million in 2008. This improvement was driven by lower R&D and G&A expenses and the absence of the $9.9 million one-time charge for acquired in-process R&D recorded in 2008 (Ercole Biotech acquisition).
• Net Loss Increase: Despite the lower operating loss, the net loss increased to $25.2 million. This was caused by a $9.2 million non-cash expense related to the mark-to-market valuation of warrant liabilities, driven by an increase in the company's stock price.
• Financing Activity: Cash balances increased by $36.9 million, resulting from equity financings in January and August 2009.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Management expects 2010 operating expenditures (net of government funding) to be approximately $23 to $27 million.
• The company anticipates completing remaining government contract activity and receiving approximately $13.3 million in unbilled revenue in 2010 and early 2011.
• Future profitability depends on raising additional capital, completing product development, and securing regulatory approvals.

Key Risks and Contingencies:

• Government Funding Reliance: Critical antiviral programs (Ebola, Marburg, H1N1) depend on U.S. Department of Defense contracts. Termination or funding delays could materially impact financial condition.
• Regulatory Approval: Products are in early clinical stages. Approval under the "Animal Rule" for Ebola and Marburg is untested and carries uncertainty.
• Capital Needs: The company has an accumulated deficit of $275.5 million and expects to incur losses for the foreseeable future. Additional capital will be required beyond the next 12 months.
• Strategic Partnership Failure: In November 2009, partner Cook Group discontinued development of the AVI-5126 drug-eluting stent due to high restenosis rates, eliminating a potential commercialization pathway.

Investor Verification Checklist

• Government Contract Status: Verify the renewal status and funding certainty of DTRA contracts for Ebola, Marburg, and H1N1 programs, which constitute the majority of revenue.
• Warrant Liability Volatility: Monitor the impact of stock price fluctuations on the non-cash warrant valuation expense, which significantly distorts net loss figures.
• Cash Burn Rate: Confirm the timeline for the next capital raise, as current cash is projected to last only 12 months excluding future government billings.
• Clinical Trial Progress: Review updates on the Phase 1/2 systemic clinical trial for AVI-4658 (Duchenne Muscular Dystrophy) and the status of the FDA clinical hold.
• Real Estate Disposition: Track the sale of the Corvallis, Oregon facility listed for sale at $2.5 million to assess potential cash inflows or impairment charges.